Early Stage Researchers EDUCational Programme on
Factor VIII Immunogenicity
The EDUC8 training network represents a novel, innovative platform for studying the immunogenicity of therapeutic pro-coagulant factor VIII (FVIII). Within the EDUC8 training network, the focused and integrated efforts of eight early stage researchers (ESRs) will allow the identification of drug- and patient-related risk factors for the development of neutralizing anti-FVIII antibodies and development of innovative protocols for inducing tolerance to FVIII. The ESRs will receive training from highly skilled experts from both the private and academic sector. In addition, training by leading clinical experts and by patient-driven organizations will provide a strong translational impact to the proposed studies. Dissemination of the results obtained within the EDUC8 consortium to patients, clinical experts, other healthcare professionals and industry is ensured by the inclusion of the European Haemophilia Consortium (EHC) and the European Alliance on Haemophilia and Allied Disorders (EAHAD).
Overall, the EDUC8 consortium will deliver eight highly skilled, entrepreneurial broadly trained experts in the exponentially expanding area of immunogenicity of biotherapeutics”. In view of the rapid increasing pace of novel biotherapeutics and biosimilars entering the European market, the delivery of eight experts on anti-drug antibodies (ADA) by the EDUC8 consortium is very timely and important in order to tackle undesirable clinical complications. Well-trained experts on novel approaches for diagnosis and treatment of ADA are desperately needed to alleviate the financial burden on healthcare budgets lined to the immunogenicity of novel and existing biotherapeutics in Europe.